Application Report

High throughput screening for mode-of-action on Na\textsubscript{v}1.4

Qube, an ideal tool for profiling large compound libraries on voltage-gated sodium channels.

Summary

- Constantly high success rates (99% in three experiments)
- Giga-ohm seal resistances in almost all wells
- Very low data spread
  - All CV values of DMSO control below 10%
  - No false positives with cut-off criteria 3 X SD
  - Z' constantly greater 0.75
- Discrimination between different modes of inhibition (state-dependency)
- Up to 384 individual IC\textsubscript{50} values (3072 data points) determined in just one experiment
- Using Qube in combination with stacker it would be possible to determine up to 7680 IC\textsubscript{50} (60,000 data points) per 24 hours.

Introduction

Voltage-gated sodium channels (VGSC) play a pivotal role in initiating and propagating action potentials in excitable cells. The family of VGSC consists of 9 known, human \(\alpha\)-subunits (Na\textsubscript{v}1.1 – 9) that exhibit a high degree of sequence homology. Similar biophysical and pharmacological properties among the different subtypes are a result of this homology (Yu & Catterall, 2003). VGSC have long been in the focus of drug development as their activity was linked to neuronal disorders including epilepsy and chronic pain. The relevance of these channels was further boosted by recent studies that have revealed further roles of VGSC in health and disease such as autism, migraine, multiple sclerosis, cancer as well as muscle and immune system dysfunctions (Eijkelkamp et al., 2012).

For example, a gain-of-function mutation of Na\textsubscript{v}1.4 can lead to membrane hyperexcitability that causes uncontrolled repetitive muscle fiber discharges and eventually results in myotonia or paralysis (England & De Groot, 2009). Use-dependent inhibitors such as flecainide or other lidocaine analogues can be used in the treatment of some of these conditions as they preferentially inhibit action potentials with high frequencies and thus reduce muscle contractions in the patients (Eijkelkamp et al., 2012).

A high-fidelity patch clamp set up is necessary to discover such a use-dependent drug. Qube is a second generation automated patch clamp system that fulfills this requirement and allows for testing of many thousands of compounds per day in an unattended fashion. Using Qube in a drug development cascade allows to ask the right questions during the primary screen, making a follow-up validation study obsolete.

In the present study, we used the TE671 cell line (ATCC) that endogenously expresses Na\textsubscript{v}1.4 to develop an assay with high success rate and reproducibility, suitable for a high-throughput screening (HTS) campaign.

Na\textsubscript{v}1.4 is encoded by the SCN4A gene and is predominantly expressed in skeletal muscles. The channel is driving depolarization of the membrane potential in these cells and is thereby responsible for propagation of the action potential that eventually controls muscle contraction. There are currently 5 mutations in the SCN4A gene described that are either linked to hypertonia (myotonia) or to muscle weakness (Jurkat-Rott et al., 2010).
Results and discussion

A 384-well based HTS assay was developed using the Qube platform that allows for reproducible testing of many thousands of compounds per day. In a first step, quality parameters such as capacitance and seal resistance were determined. Figure 1 shows total capacitance and total resistance before and after application of the whole-cell pressure pulse. As expected, a 4 s long negative pressure pulse to -250 mbar ruptured the membrane patch as indicated by the increase in capacitance. High seal resistances were already measured in the on-cell configuration, additional waiting time and the whole-cell rupture further increased seal resistance resulting in a mean of 1.5 ± 0.5 GΩ/cell in the whole-cell configuration.

To be able to discriminate between inhibition of different Na,1.4 channel states, a partial inactivation protocol was used (Figure 2). A voltage pre-step to -120 mV ensured that the entire channel population was in the closed state prior to a first stimulation (P1) to -20 mV that caused a concerted opening of all channels. A following step to -70 mV kept a portion of the channels in the inactivated state upon a second stimulation to -20 mV (P2). State-dependent inhibitors, such as tetracaine, will preferentially inhibit the inactivated state, thus resulting in a more pronounced inhibition of the peak current measured at the second stimulation following the -70 mV voltage step.
To study compound effects on Na\textsubscript{v}1.4 a set up was chosen that included a baseline, a test period and a reference period (Figure 3). In more detail, two saline period were applied with 1 and 4 min duration, to establish a stable baseline. During these periods, the voltage protocol described in Figure 2 was continuously applied in 15 s intervals, to monitor changes in peak current. Next, cells were exposed to the test compound or respective negative control for 4 min. Each experiment was finished with application of a supramaximal concentration (on P2) of tetracaine (30 µM) as reference. Average peak currents recorded during the last 3 sweeps of a period were used for further analysis. Relative inhibition was calculated using the following relationship (Equation 1):

\[
\text{% Inhibition} = \frac{I(\text{Test}) - I(\text{Baseline})}{I(\text{Reference}) - I(\text{Baseline})} \times 100
\]

Studying compound effects on P2 poses often a challenge as for some VGSC assays the voltage for half-inactivation (V\text{1/2}) shifts during the experiment. As a result of this, the number of channels that are in the inactivated state when clamped at -70 mV varies throughout the experiment, causing unstable P2 current amplitudes over time. Therefore, we characterized current stability of the Na\textsubscript{v}1.4 assay in a plate uniformity experiment. During this experiment, column 1-23 were exposed to 0.1% DMSO and column 24 was used as positive control with 30 µM tetracaine. Results are shown in Figure 4: the relative current inhibition of P2 is represented for each well of the 384-well QChip. Using this data, coefficient of variation values were calculated for all columns and all rows. All CV values were below the quality criteria of 10%, indicating a high degree of uniformity. The success rate of this experiment, with the filter criteria R\text{total} > 0.3 GΩ, was 99%. The high quality of the assay is further reflected in the Z’ value that was 0.89 and Z = 0.8. Z’ was calculated using column 23 and column 24 and input values from column 1-23 as well as column 24 were used to calculate Z.

In a large compound screen, a hit is often defined as a compound that inhibits current by more than 3 times the standard deviation (SD) of the negative control. A histogram plot of the relative current inhibition of P2 is shown in Figure 5 with mean and 3 x SD indicated by a bold and a dashed line, respectively. None of the wells receiving DMSO control during the experiment had a value exceeding the 3 x SD (27%) cut-off. Therefore, no false positives were detected in the assay.

In a next step, the assay was characterized pharmacologically using the state-dependent VGSC inhibitor tetracaine. Two different approaches were chosen to record concentration response curves (CRC), a non-cumulative and a cumulative. For the non-cumulative CRC experiment, only one concentration of tetracaine was applied per well and data from several wells were compiled to generate one CRC. For this experiment, the same experimental set up as described in Figure 3 was employed. The cumulative CRC experiment is much more challenging for the assay, as in such an experiment, the whole range of concentrations are applied to each well. This requires a high stability over an extended period of time and through several liquid additions.
Sophion

Figure 5: Histogram plot of DMSO control % inhibition data (black) and 30 µM tetracaine (red). The mean % inhibition of DMSO control is shown as bold line and 3 x SD (27%) are indicated with dashed lines. All control data lie within 3 x SD, hence using this cutoff criteria, no false positives were detected in the assay.

Figure 6 shows the compound plate set up used for the non-cumulative concentration response experiment. Each row of a 384-well compound plate contained 7 concentrations of tetracaine in triplicates. Using n = 1 per concentration, it was possible to construct 3 CRCs per row and thus 48 CRCs per experiment. Two negative controls (0.1% DMSO, column 22-23) and a positive control (30 µM tetracaine, column 24) were included to monitor assay stability over time.

Results of the non-cumulative CRC experiment are shown in Figure 7. Both data from P1 and P2 were fitted using a Hill equation. As expected, the highest tetracaine concentration applied (30 µM) only partially inhibited P1 resulting in a poorly defined CRC. The calculated IC_{50} values of P1 (IC_{50} = 30 ± 6 µM (SD; n= 48)) can therefore only be consider as a rough estimate. In contrast, 30 µM tetracaine completely inhibited Na_{V}1.4 – mediated current at P2, confirming its preferential inhibition of the inactivated state. CRCs of P2 are well aligned and exhibit small variation with IC_{50} = 2.0 ± 0.3 µM (SD; n= 48; see also Figure 9). The success rate for this experiment, with the filter criteria R_{total}> 0.3 GO, was 99% and Z’ calculated from column 23 (negative control) and 24 (positive control) was 0.77.

A cumulative CRC was recorded using 2 saline periods with 1 and 4 min duration followed by 8 increasing concentrations of tetracaine with each 2 minute exposure time (Figure 8, left). A negative (0.1% DMSO) and positive control (30 µM tetracaine) were added to column 23 and 24, respectively. This set up allowed to record 352 individual CRCs with each 8 concentrations in one experiment (Figure 8, right). IC_{50} values calculated from this experiment (IC_{50} = 1.8 ± 0.4 µM (SD; n= 348); see also Figure 9) were in line with values obtained for the non-cumulative CRC experiment. Success rate of this experiment was 99% and Z’ was 0.84.
Fig. 8: Cumulative, 8 point CRC of tetracaine on P2. Top: P2 peak current over time. Following two saline periods of 1 and 4 min duration, increasing concentrations of tetracaine, as indicated, were applied to each cell. Bottom: Plate view showing individual CRCs of each well. Column 23 and 24 were exposed to a 0.1% DMSO and 30 µM tetracaine control, respectively. The corresponding IC$_{50}$ values are presented in Figure 9.

Fig. 9: Histogram plot of IC$_{50}$ values of tetracaine on P2. Data of the non-cumulative CRC are shown in the upper panel (data from Figure 7), values calculated from cumulative CRCs are shown in the lower panel (data from Figure 8). IC$_{50}$ values of both approaches were in good agreement with each other with IC$_{50}$ = 2.0 ± 0.3 µM (SD; n= 48) for the non-cumulative and IC$_{50}$ = 1.8 ± 0.4 µM (SD; n= 348) for the cumulative concentration response experiment.
Methods

Cells

- TE671 cells endogenously expressing Nav1.4 were cultured at 37°C and 5% CO2 in Dulbecco Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/ml Penicillin and Streptomycin, and 2 mM sodium-pyruvate. Cells were purchased at ATCC.

On the day of the experiment, cells were harvested using Detachine and kept in serum-free media until further use. Qube’s automated cell preparation unit was used to resuspend cells in saline just before the start of the experiment.

Electrophysiology

- Whole cell access was gained using a single pressure pulse to -250 mbar for 4 s. Cells were afterwards clamped at Vhold = -90 mV and -10 mbar.
- All experiments were done using multihole QCChips (10 holes/well).
- Data was analyzed using Sophion’s Analyzer and Origin 7.5 (OriginLab) software. Data are represented as mean ± SD.

References: